Table 3.
Adverse events
| Control | Prostacyclin | |
|---|---|---|
| Bleeding, no. (%) | 11 (15%0.8–26%) | 9 (13%, 6–22%) |
| Transfusion requirement (RBC), no. (%)i | 24 (34%, 23–46%) | 24 (34%, 23–46%) |
| Thrombotic event, pulmonary embolism or coagulopathy | 5 (7%, 2–15%) | 5 (7%, 2–15%) |
| Need for renal replacement therapy | 17 (24%, 14–35%) | 15 (21%, 12–32%) |
| Gastrointestinal complications, no. (%) | 13 (18%, 10–29%) | 7 (9%, 4–19%) |
| Neurologic complications, no. (%) | 2 (3%, 0.3–10%) | 4 (6%, 2–14%) |
| Cardiovascular complications, no. (%) | 17 (24%, 14–35%) | 13 (18%, 10–29%) |
i142 patients included, results in brackets are 95% CIs for proportions